John Jansen
Overview
Explore the profile of John Jansen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
306
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kappel D, Rees E, Fenner E, King A, Jansen J, Helthuis M, et al.
Eur Neuropsychopharmacol
. 2024 Feb;
80:47-54.
PMID: 38310750
Clozapine is the only licensed medication for treatment-resistant schizophrenia (TRS). Few predictors for variation in response to clozapine have been identified, but clozapine metabolism is known to influence therapeutic response...
2.
Lock S, Legge S, Kappel D, Willcocks I, Helthuis M, Jansen J, et al.
Schizophrenia (Heidelb)
. 2023 Oct;
9(1):74.
PMID: 37853043
Clozapine is effective at reducing symptoms of treatment-resistant schizophrenia, but it can also induce several adverse outcomes including neutropenia and agranulocytosis. We used linear mixed-effect models and structural equation modelling...
3.
Xu C, Sun Y, Jansen J, Li M, Wei L, Wu Y, et al.
Tissue Eng Part C Methods
. 2023 Apr;
29(5):197-215.
PMID: 37071160
Implant-supported dental prosthetics are widely used in dental practice. Sufficient peri-implant bone tissue is a crucial prerequisite for the long-term success of this treatment, as insufficient peri-implant bone volume hampers...
4.
Pardinas A, Kappel D, Roberts M, Tipple F, Shitomi-Jones L, King A, et al.
Lancet Psychiatry
. 2023 Feb;
10(3):209-219.
PMID: 36804072
Background: The antipsychotic, clozapine, is the only licensed drug against the treatment-resistant symptoms that affect 20-30% of people with schizophrenia. Clozapine is markedly underprescribed, partly because of concerns about its...
5.
Kappel D, Legge S, Hubbard L, Willcocks I, OConnell K, Smith R, et al.
Biol Psychiatry
. 2022 Oct;
93(2):149-156.
PMID: 36244804
Background: Treatment-resistant schizophrenia affects approximately 30% of individuals with the disorder. Clozapine is the medication of choice in treatment-resistant schizophrenia, but optimizing administration and dose titration is complex. The identification...
6.
Parker T, Jansen J, Behroozmand A, Halkjaer M, Thorn P
Ground Water
. 2022 Aug;
60(5):606-618.
PMID: 35923137
Increasing water stress and decreasing supplies caused by growth and climate variability have expanded demand for managed aquifer recharge (MAR) projects to provide water supply resilience. Some of the most...
7.
Diba M, Jansen J
Tissue Eng Part C Methods
. 2022 Jul;
28(7):287-288.
PMID: 35834599
No abstract available.
8.
Willcocks I, Legge S, Nalmpanti M, Mazzeo L, King A, Jansen J, et al.
Front Pharmacol
. 2021 May;
12:658734.
PMID: 33959025
Up to one-third of those with schizophrenia fail to respond to standard antipsychotics and are considered to have treatment-resistant schizophrenia, a condition for which clozapine is the only evidence-based medication....
9.
de Lacerda Schickert S, Pinto J, Jansen J, Leeuwenburgh S, van den Beucken J
Biomater Sci
. 2020 Jun;
8(15):4239-4250.
PMID: 32579633
Vertebral compression fractures (VCFs) are a very common problem among the elderly, which ultimately result in severe pain and a drastically reduced quality of life. An effective treatment for VCFs...
10.
Alshehri F, Alshehri M, Sumague T, Niazy A, Jansen J, van den Beucken J, et al.
Materials (Basel)
. 2019 Nov;
12(21).
PMID: 31684138
Dental implants with surface-porous designs have been recently developed. Clinically, peri-implant bone grafting is expected to promote early osseointegration and bone ingrowth when applied with surface-porous dental implants in challenging...